Sandoz-Henlius $322m biosimilar deal starts with three blockbusters and could expand to 10 assets
Sandoz gains ex-China commercialization rights to an initial biosimilar portfolio while Henlius retains development, manufacturing and supply responsibilities under a collaboration worth up to $322 million.
